An analysis published on Yahoo Finance suggests Aehr Test Systems (NASDAQ:AEHR) is a better investment than C3.ai (NYSE:AI) for 2026. The analysis highlights Aehr's focus on essential chip testing equipment for high-growth markets, noting its record quarterly bookings and backlog, with guidance for 2-3x revenue growth in the coming fiscal year. In contrast, C3.ai, an enterprise AI software provider, reported a FY2026 revenue decline of nearly 35.7% to approximately $250.3 million and a net loss of close to $470.4 million. Aehr Test Systems' FY2026 revenue was close to $50.0 million, a 15.2% decline, with a net loss of approximately $7.1 million, but the analysis emphasizes its stronger operational focus and growth trajectory.